inhibition of glial scarring in the injured rat brain by a recombinant human monoclonal antibody to...
TRANSCRIPT
Inhibition of glial scarring in the injured rat brain by arecombinant human monoclonal antibody to transforminggrowth factor-b2
Ann Logan, Jonathan Green1, Allison Hunter2, Ronald Jackson1 and Martin Berry2
Department of Medicine, University of Birmingham, Birmingham B15 2TT, UK1Cambridge Antibody Technology Limited, The Science Park, Melbourn, Royston, Cambridgeshire SG8 6JJ, UK2Department of Anatomy and Cell Biology, UMDS, Guy's Hospital, London SE1 9RT, UK
Keywords: central nervous system, ®brosis, ®brotic neuropathology, immunoneutralization, transforming growth factor b
Abstract
The transforming growth factor-bs (TGF-bs) are potent ®brogenic factors implicated in numerous central nervous system (CNS)pathologies in which ®brosis and neural dysfunction are causally associated. In this study, we aim to limit the ®brogenic process in amodel of CNS scarring using a recombinant human monoclonal antibody, derived from phage display libraries and speci®c to theactive form of the TGF-b2 isoform. The implicit inference of the work was that, as such antibodies are potential pharmacologicalagents for the treatment of human CNS ®brotic diseases, validation of ef®cacy in a mammalian animal model is a ®rst step towardsthis end. Treatment of cerebral wounds with the anti-TGF-b2 antibody led to a marked attenuation of all aspects of CNS scarring,including matrix deposition, formation of an accessory glial-limiting membrane, in¯ammation and angiogenesis. For example, in thewound, levels of: (i) the connective tissue components ®bronectin, laminin and chondroitin sulphate proteoglycan; and (ii) wound-responsive cells including astrocytes and macrophages/microglia, were markedly reduced. Our ®ndings suggest that such syntheticanti-®brotic TGF-b antibodies are potentially applicable to a number of human CNS ®brotic diseases to arrest the deposition ofexcessive extracellular matrix components, and maintain and/or restore functional integrity.
Introduction
Fibrosis is caused by the excessive deposition of extracellular matrix,
which can compromise the function of the tissue involved. The
transforming growth factor-bs (TGF-bs) are potent ®brogenic factors
which have been implicated in a broad diversity of biological actions,
including enhancement of wound healing, stimulation of extracellular
matrix synthesis, modulation of in¯ammatory cell in®ltration,
immunosuppression and neuroprotection (Cui & Ackhurst, 1996;
Pratt & McPherson, 1997). A role for TGF-bs has been suggested in
numerous central nervous system (CNS) pathologies in which ®brosis
and neural dysfunction are causally associated. For example, in post-
trauma brain and spinal cord scarring (Logan et al., 1992, 1994); post-
surgical arachnoiditis (Logan & Berry, 1994), haemorrhagic stroke
(Krupinski et al., 1996) and sub-arachnoid haemorrhage (Kitazawa &
Tada, 1994); TGF-bs may also promote plaque development in
Alzheimer's disease and Downs syndrome (Wyss-Coray et al., 1997).
In all of these conditions, TGF-b levels are raised in the cerebrospinal
¯uid (CSF) and locally in damaged neural tissue. For example, after
CNS traumatic damage, we have demonstrated an elevation of the
TGF-b1 isoform, initially derived from haematogenous cells and later
supplemented by endogenous local synthesis by neurons and glia in
the damaged neuropil, and by choroid plexus cells of the impaled
lateral ventricle leading to raised cytokine levels in the CSF (Logan
et al., 1992, 1994). As part of a separate study, to be reported
elsewhere, we have also shown that the TGF-b2 mRNA and protein is
strongly upregulated to a peak of expression in wounds at 5±7 days
following penetrating CNS injury (C. Lagord, M. Berry and A.
Logan, unpublished results). In particular, TGF-b2 is found localized
to reactive astrocytes of the damaged neuropil. These observations
imply a potential role for both TGF-b isoforms in the CNS injury
response.
The most direct evidence to date for a ®brogenic role for TGF-bisoforms in the pathophysiology of CNS ®brosis comes from
experiments in the lesioned brain. On the one hand, raised levels of
TGF-b1 are correlated with the deposition of scar material in such
lesions, whilst immunoneutralization with a turkey polyclonal TGF-
b1 antibody markedly inhibits ®brogenic scarring, albeit with an
accompanying enhanced in¯ammatory response (Logan et al., 1994).
Nothing is known of the role of the TGF-b2 isoform in the ®brogenic
process in the CNS. It is implicit from previous observations that
attenuation of either excess or inappropriate matrix deposition using
TGF-b-related anti-®brotic agents may limit the progress of the
pathogenic process, with anticipated clinical bene®ts. Although the
principle of inhibition of ®brogenesis by TGF-b immunoneutraliza-
tion is established, the reported exacerbation of in¯ammation
associated with the use of animal-derived polyclonal antibodies in
general, and TGF-b1 polyclonal antibodies in particular, may limit
their therapeutic potential for the treatment of patients with ®brotic
disease.
Selection from phage display libraries of human single-chain Fv
fragments allows the preparation of speci®c neutralizing recombinant
human monoclonal antibodies against human self antigens. Although
their therapeutic effectiveness in vivo remains to be established, such
Correspondence: A. Logan, as above.E-mail: [email protected]
Received 31 July 1998, revised 22 February 1999, accepted 1 March 1999
European Journal of Neuroscience, Vol. 11, pp. 2367±2374, 1999 ã European Neuroscience Association
synthetic antibodies would be preferred therapeutic molecules due to
their increased speci®city and reduced immunogenicity. Here, we
report for the ®rst time in vivo ef®cacy of a recombinant human
monoclonal antibody, isolated from a phage display library and
speci®c to the active form of the TGF-b2 isoform. The antibody
signi®cantly inhibits ®brogenesis, glial scarring and, interestingly,
in¯ammation in penetrating incisional wounds of the rat brain.
Methods
Neutralizing TGF-b2 antibody
6B1 IgG4 (immunoglobulin) is a recombinant antibody with a fully
human sequence, directed against TGF-b2. The VH and VL variable
regions of 6B1 were obtained by selection on active human TGF-b2
from phage display libraries of human single-chain Fv antibody
molecules at Cambridge Antibody Technology (Melbourn, Cambrid-
geshire, UK). A whole antibody molecule of the IgG4 isotype was
then constructed by recombinant techniques and expressed in NS0
myeloma cells and puri®ed. The recombinant antibody, termed 6B1,
has been well characterized (Thompson et al., 1999). For example: (i)
it has a high af®nity for TGF-b2 with a dissociation constant of
0.89 nM, as determined by binding to TGF-b2 using the BIACore
biosensor (Table 1); (ii) it shows approximately 9% cross-reactivity
with TGF-b3 (dissociation constant, 10 nM) compared with TGF-b2;
(iii) it has no detectable binding to TGF-b1; (iv) it is speci®c for the
active form of TGF-b2 and does not signi®cantly bind the latent
form; (v) it strongly neutralizes the antiproliferative effect of TGF-b2
in bioassays using TF1 human erythroleukaemia cells (Randall et al.,
1993) (Table 1) with an IC50 of 1±2 nM; (vi) it has strong inhibition of
binding of TGF-b2 to cell surface receptors in a radioreceptor assay
using A549 cells (Lucas et al., 1991) (Table 1); (vii) it has some
ability to neutralize and inhibit TGF-b3 binding, as would be
expected from the 9% cross-reactivity; (viii) it has no signi®cant
ability to inhibit or neutralize TGF-b1 binding as would be expected
from the undetectable binding by BIACore; (ix) it shows no
detectable cross-reactivity with related or unrelated antigens by
immunocytochemistry and ELISA; and (x) it binds to active TGF-b2
from human, rat, mouse, pig and rabbit.
The control antibody used in these experiments, termed 2G6 IgG4,
is an isotype-matched recombinant human IgG4 antibody containing
the variable heavy (VH) variable region of a humanized antibody,
B1.8, directed against 4-hydroxy-3-iodo-5-nitrophenylacetic acid
(NIP) and the variable light (VL) variable region of a humanized
antibody, D1.3, directed against lysozyme. 2G6 IgG4, expressed in
NS0 cells and puri®ed as for 6B1 IgG4, does not bind to TGF-bisoforms and has been shown by immunocytochemistry not to bind to
a panel of human tissues.
Surgery and experimental procedures
Surgical procedures and animal care were licensed and carried out
according to British Home Of®ce guidelines. Stereotactic lesioning of
the cerebral cortex and intraventricular cannulation were executed
exactly as described by us elsewhere (Logan et al., 1994; Logan &
Berry, 1994). Adult female 200±250 g Wistar rats were assigned to
three treatment groups, each receiving: (i) vehicle (saline) plus 0.1%
autologous rat serum to negate the protein concentration of the test
reagents (10 animals); (ii) vehicle plus 200 ng/day 2G6 (an irrelevant
IgG4) immunoglobulin (six animals); (iii) vehicle plus 200 ng/day
human anti-TGF-b2 (6B1 IgG4) immunoglobulin (nine animals). On
day 0 of the experiment, a stereotactically de®ned unilateral
incisional lesion was placed through the cerebral cortex into the
lateral ventricle at the same time as ipsilateral placement of a
permanent intraventricular cannula. Reagents (5 mL) were perfused
into the lesion by immediate and subsequent daily injection for
10 days under halothane anaesthesia through a cannula into the lateral
ventricle. The body weights of each animal were monitored daily and
no signi®cant differences were noted between the treatment groups at
any time point. After 14 days, animals were killed and their brains
processed for either ¯uorescence or peroxidase immunohistochemical
analysis of the lesion site.
Histology and immunohistochemistry
Brains were processed into polyester wax and 7-mm sections of the
lesion site stained by ¯uorescent immunohistochemistry to detect
glial ®brillary acidic protein (GFAP)-positive astrocytes (using a
polyclonal rabbit anti-GFAP antibody from Dakopatts, Ely, Cambs.,
UK at a dilution of 1 : 250), ED1-positive macrophages and microglia
(using a monoclonal mouse anti-rat ED1 antibody from Serotec,
Oxford, UK at a dilution of 1 : 200), ®bronectin (using a polyclonal
rabbit anti-®bronectin antibody from Dakopatts at a dilution of
1 : 100), laminin (using a polyclonal rabbit anti-laminin antibody
from Dakopatts at a dilution of 1 : 100), and peroxidase immunohis-
tochemistry to detect chondroitin sulphate proteoglycan (CSP) (using
a monoclonal anti-CSP antibody, C-8035, from Sigma, Poole, UK,
which recognizes CS56 at a dilution of 1 : 200). Both methods are
described in detail elsewhere (Logan et al., 1994; Logan & Berry,
1994). Note that in all sections viewed under ¯uorescent light,
in¯ammatory macrophages and microglia showed red auto¯uores-
cence. Also, the laminin antibody detected the basement membrane
component of both the glia limitans and the neuropil microvascu-
lature.
Quantitation of immunohistochemistry
In all cases, the effects of each treatment on the CNS wounding
response were quanti®ed by image analysis of ¯uorescently-labelled
sections taken from a de®ned anatomical plane through the lesion site
(Logan et al., 1994; Logan & Berry, 1994) using a Leitz confocal
microscope linked to a Biorad MRC500 laser scanning system. The
relative intensity of ¯uorescence in terms of the mean integrated pixel
intensity was expressed as the integrated ¯uorescent intensity/mm2 in
de®ned and exactly equivalent areas at a constant magni®cation for
each animal. Similarly, the density of peroxidase staining/mm2 was
measured at a constant magni®cation in sections under bright ®eld
using a Leitz microscope video-linked to a Macintosh computer and
National Institutes of Health Image Analysis software.
Results
Cellular effects of TGF-b2 immunoneutralization
By 14 days following an untreated penetrating lesion of the cerebral
cortex, a mature contracted scar is formed at the wound site, which
has a dense, matrix-rich core which is surrounded by a limiting glial
membrane (Fig. 1). Residual ED1-positive macrophages and
TABLE 1. Binding and biological activity properties of 6B1 IgG4 for TGF-bisoforms
TGF-b1 TGF-b2 TGF-b3
Kd (dissociation constant) (nM) 0.89 10.0IC50, TF1 neutralization assay (nM) > 100 2 11IC50, A549 radioreceptor assay (nM) > 400 0.05 4
2368 A. Logan et al.
Ó 1999 European Neuroscience Association, European Journal of Neuroscience, 11, 2367±2374
FIG. 1. Appearance of a mature untreated®brotic scar in the lesioned cerebralhemisphere. A section through a de®ned planeof the site of an untreated cerebral lesion at14 dpl, stained with antibodies that bind GFAP(a marker of reactive astrocytes), laminin,®bronectin and ED1 (a marker of macrophagesand microglia). Antibody binding is detectedwith ¯uorescein-conjugated secondaryantibodies to show the dense ®brous matrix inthe core of the wound which is surrounded bya glial membrane. The scar tissue extendsdown from the cerebrum surface between thecut surfaces of the neuropil of the cortex andreveals the extent of the de®ned lesion. Bar,100 mm.
Inhibition of glial scarring in the injured brain 2369
Ó 1999 European Neuroscience Association, European Journal of Neuroscience, 11, 2367±2374
FIG
.2.
Cel
lula
ref
fect
so
fan
tib
ody
trea
tmen
t.S
ecti
on
sth
roug
ha
de®
ned
pla
ne
of
the
site
of
ace
rebra
lle
sion
at14
dpl
com
par
ing
the
effe
cts
of
infu
sion
wit
hsa
line
(ai±
v)
and
anti
-TG
F-b
2Ig
G4
(6B
1)
(bi±
v)
on
imm
uno
reac
tiv
e®
bro
nec
tin
(i),
lam
inin
(ii)
,C
SP
(iii
),E
D1
-posi
tive
mac
rophag
esan
dm
icro
gli
a(i
v),
and
GF
AP
-posi
tive
astr
ocy
tes
(v).
Sec
tions
are
stai
ned
wit
h¯
uore
scen
t-(g
reen
/yel
low
)or
per
oxid
ase-
(bro
wn,
CS
Po
nly
)co
nju
gat
edan
tib
od
ies;
inth
efo
rmer
,th
ep
ath
of
the
lesi
on
ism
arked
by
resi
dual
auto
¯uore
scen
tm
acro
phag
es/m
icro
gli
a(n
ote
:re
d¯
uore
scen
ce=
auto
¯uore
scen
tin
¯am
mat
ory
cell
s).
Bar
,100
mm.
2370 A. Logan et al.
Ó 1999 European Neuroscience Association, European Journal of Neuroscience, 11, 2367±2374
FIG. 3. Quantitative image analysis of the wounding response after cerebral lesion. The effects of saline, control IgG4 (2G6) and anti-TGF-b2 IgG4 (6B1) on thelevels of immunoreactive ®bronectin (i), laminin (ii), CSP (iii), ED1-positive macrophages and microglia (iv), and GFAP-positive astrocytes (v), within cerebralwounds at 14 dpl. Fluorescent- and peroxidase- (CSP only) stained images of sections through a de®ned plane of the lesion site were digitized, and either theintegrated ¯uorescent intensity or the density of peroxidase-related staining quanti®ed in exactly equivalent areas. *Signi®cant reduction compared with salinecontrol, P < 0.05. **Signi®cant reduction compared with control 2G6 IgG4, P < 0.05. ***Signi®cant reduction compared with saline control and control 2G6 IgG4,P < 0.05.
Inhibition of glial scarring in the injured brain 2371
Ó 1999 European Neuroscience Association, European Journal of Neuroscience, 11, 2367±2374
activated microglia are still apparent at this time point. In rats treated
with control 2G6 IgG4, the ®brotic scars were qualitatively
equivalent to or indistinguishable from those in lesioned untreated
or saline-treated rats. When quanti®ed, there was an apparent
reduction in immunoreactive laminin and ®bronectin in the wounds
compared with controls, but this reduction was marginal and never
reached statistical signi®cance. The scar contracted into a typical
dense permanent trilaminar glial/®brotic complex (Fig. 2ai-v), the
core of which was laid down by meningeal ®broblasts, and was rich
in ®bronectin (Fig. 2ai) and CSP (Fig. 2aiii). Residual macrophages
and microglia occupied the core and bordering viable neural tissue
(Fig. 2aiv), both of which were separated by a laminin-rich basal
lamina of the glia limitans externa (Fig. 2aii) and undercoated by end-
feet and processes of reactive astrocytes of the glia limitans (Fig.
2av). These three layers extended throughout the lesion and became
contiguous with the complementary laminae of the glia limitans
externa at the pial surface of the cerebrum. The basement membrane
of neuropil blood vessels was also visualized with the anti-laminin
antibody and revealed the angiogenic response in the tissue
surrounding the wound (Fig. 2aii).
In contrast, in every anti-TGF-b2 (6B1 IgG4)-treated rat, the glia
limitans (comprising abutted astrocyte processes and a basal lamina)
was reconstructed only in the sub-pial layers of the lesioned cortex,
and thus normal wound closure was limited to this site. In the deeper
cortical layers, the numerous activated astroglia neither organized
into the expected limiting membrane (Figs 2bv and 3v), nor laid down
a laminin-rich basal lamina in the wound (Fig. 2bii). Little or no
®bronectin was deposited in the core of the wound (Figs 2bi and 3i),
and there was signi®cantly less CSP deposited in the scar and
surrounding neuropil (Figs 2biii and 3iii). Hence, the cut neuropil
surfaces became apposed without the intervention of a glial/matrix
scar. The angiogenic activity of TGF-bs was also suppressed as the
laminin-rich basal laminae of wound-related blood vessels were
rarely seen in the neuropil surrounding a TGF-b2 neutralized wound,
although the normal small diameter microvasculature was apparent
(Fig. 2bii). Finally, there was a signi®cant reduction in the numbers of
EDI-positive macrophages and microglia in the wound and
juxtaposed neuropil at 14 days post-lesion (dpl, Figs 2biv and 3iv),
indicating immunosuppression.
Statistics
The data of each group were compared using the Wilcoxon
ranking test. Comparison of the anti-TGF-b2 antibody-treated data
with those of the saline control showed a signi®cant reduction in
speci®c ¯uorescence/peroxidase staining (P < 0.05) for ED1,
®bronectin, laminin and CSP. There was a statistically insignif-
icant reduction of ®bronectin, laminin and CSP deposition by the
control irrelevant 2G6 IgG4 when compared with the saline
control. Nonetheless, the immuno¯uorescence/peroxidase staining
observed in the group treated with 6B1 IgG4 compared with that
treated with 2G6 IgG4 was signi®cantly less (P < 0.05) for ED1,
GFAP and ®bronectin. Total scarring was determined by
combining the data for ®bronectin- and laminin-stained sections.
Because of the differences in intensity of staining of the two
molecules, the data for the ®bronectin and laminin images were
ranked separately for each animal (from 1 for the lowest to 25
for the highest). A composite score was then derived by adding
the two ranked scores for each rat. The analysis showed a near-
signi®cant reduction in total scarring for the 6B1 IgG4-treated
group compared with the control 2G6 IgG4-treated group
(P < 0.1).
Discussion
The technique of preparation of human antibodies against human
self-antigens (Grif®ths et al., 1993; Marks et al., 1991; Vaughan et al.,
1996) was adapted to select VH and VL variable regions of the
neutralizing recombinant human monoclonal anti-TGF-b2 antibody
from phage display libraries of human single-chain Fv antibody
molecules. We have shown that the antibody prepared binds to active
TGF-b2 from rat, mouse, pig and rabbit, as well as human. Over the
past decade, rodent antibodies against human proteins have been
humanized by transplantation of mouse CDRs into human frame-
works (Adair & Bright, 1995) leading to the application of, e.g. an
antibody against the product of the HER2/neu protooncogene
(Baselga et al., 1996) in clinical trials of metastatic breast cancer.
Fully human antibodies directly isolated from phage display libraries
are therapeutically effective in animal models against foreign
antigens, e.g. respiratory syncytial virus (Crowe et al., 1994), and
have been used to image tumours expressing human CEA in a mouse
xenograft model (Jackson et al., 1998) or ®bronectin ED-B domain
(conserved between human and mouse) in a grafted murine
teratocarcinoma mouse model (Neri et al., 1997). However, few or
no reports have been made of the therapeutic effectiveness of human
antibodies prepared against human self-antigens in vivo.
The technique of cerebral injury in rats, fully documented by us
elsewhere (Logan et al., 1994; Logan & Berry, 1994), provides a
well-characterized experimental model of wound healing and CNS
®brosis in particular, in which the anti-®brotic ef®cacy of the
recombinant monoclonal anti-TGF-b2 antibody can be tested. The
lesion penetrates the lateral ventricle, allowing antibody injected into
the ventricular cerebrospinal ¯uid to perfuse the lesion. Within these
standard lesions, a sequential cellular response occurs characterized
by haemorrhage, in¯ammation, the formation of a trilaminar glial-
matrix scar and an abortive regeneration response by the axons of
compromised neurons, which is essentially complete at 14 dpl in the
rat.
This study demonstrates that acute phase treatment of such wounds
with the recombinant human monoclonal antibody against TGF-b2
leads to a marked attenuation of all aspects of CNS scarring. The
spatially graded response to the antibody from wound depths to
cerebrum surface may re¯ect the gradient of wound perfusion, as
neutralizing IgGs are delivered from the ventricles through the base
of the wound. The suppression of in¯ammation, glial/mesenchymal
scarring and angiogenesis illustrates the widespread activities of
TGF-b2 within CNS wounds. All of the inferred activities of TGF-b2
have precedent in other experimental models. For example, TGF-bs
are known to induce chemokinesis and chemotaxis in vitro and in
vivo (Wahl et al., 1987), upregulate astrocyte production of monocyte
chemoattractant protein-1 (a potent chemoattractant and stimulator of
monocytes) (Hurwitz et al., 1995), and affect cell migration via
modulation of expression of integrins, a major class of cell adhesion
receptors and cell adhesion molecules (Ignotz et al., 1989; Heino &
Massague, 1989). These activities may be of relevance to the
apparent immunosuppression by the anti-TGF-b2 antibody observed
in this model of injury, evidenced by the reduction in both
immunoreactive macrophages and microglia in the wound. In
contrast, we have previously seen that neutralization of the TGF-b1
isoform in the same experimental model resulted in an enhanced
in¯ammatory response, with the microglial population being
particularly responsive to such treatment (Logan et al., 1994). Whilst
TGF-bs are recognized as general immunosuppressors, in the initial
stages of in¯ammation they stimulate monocyte migration (Wahl
et al., 1987), and it may be this activity which the anti-TGF-b2 IgG4
2372 A. Logan et al.
Ó 1999 European Neuroscience Association, European Journal of Neuroscience, 11, 2367±2374
has blocked. It is apparent that the immunosuppression noted with
this isoform-speci®c antibody may be therapeutically advantageous,
as it may reduce the risk of treatment initiating adverse immunolo-
gical reactions.
Others have shown that TGF-bs affect astrocyte morphology,
proliferation, migration and interaction in vitro (Pratt & McPherson,
1997). TGF-b is a potent astrocytic chemotactic agent, it reduces
cell±cell contacts and increases focal contacts, both precursors for
cell migration (Gagelin et al., 1995), and also stimulates the
development of highly branched cellular processes and multicellular
colonies, an activity reminiscent of the cell association that occurs
during formation of the glial membrane (Flanders et al., 1993;
Labourdette et al., 1990; Toru-Delbauffe et al., 1990). Immunoneu-
tralization of either the TGF-b1 (Logan et al., 1994) or TGF-b2
isoform in this model of CNS injury does not limit the extent of
reactive gliosis, but does prevent the organization of astrocytes into
the limiting glial membrane of the CNS scar. We suggest that in both
cases, the neutralizing antibodies are blocking those TGF-b-mediated
astrocyte activities which relate to astrocytic scar formation.
Many groups have demonstrated the ®brogenic effects of TGF-bs
in various models of peripheral tissue injury (see review by Cui &
Ackhurst, 1996), which supports our observations in the CNS that
inhibition of TGF-b activity causes a marked reduction in the
deposition of every matrix molecule examined, including ®bronectin,
laminin and chondroitin sulphate proteoglycan. The anti-®brotic
actions of the antibody may relate to actions on astrocytes as well as
®broblasts, as both produce a range of matrix molecules in response
to TGF-b in vitro (Flanders et al., 1993; Baghdassarian-Chalaye et al.,
1993; Wrana et al., 1986; Ignotz & Massague, 1989; Varga et al.,
1987). The ®brogenic actions of TGF-bs result from upregulating the
synthesis of multiple extracellular matrix molecules (Baghdassarian-
Chalaye et al., 1993; Wrana et al., 1986; Ignotz & Massague, 1989;
Varga et al., 1987) and protease inhibitors (Laiho et al., 1986; Lund
et al., 1987), downregulating the expression of matrix-degrading
proteases (Kerr et al., 1990), and also modulating integrin expression
and consequent ®broblast traf®cking into the wound (Heino &
Massague, 1989; Gagelin et al., 1995). Finally, the angiogenic
activity of TGF-bs is well established (Pepper, 1997; Roberts et al.,
1986), and probably explains the reduced angiogenic response seen in
the neuropil surrounding a TGF-b2 immunoneutralized CNS wound.
The apposition of the cut neuropil surfaces observed in anti-TGF-
b2 antibody-treated lesions suggests the absence of the physical, and
perhaps biochemical, barrier that the gliotic scar represents to
regenerating axons. In this study, regeneration was not rigorously
studied using axonal tracing methods, however, histologically, no
axons were seen to traverse the scar-inhibited lesion. This observation
presumably re¯ects, at least in part, the limiting supply of appropriate
neurotrophic factors required for regeneration. We suggest that, in
addition to inhibiting cicatrix formation, a strategy to mobilize the
axon growth machinery is required in order to achieve vigorous and
sustained neuron regeneration across a transection site.
In summary, we demonstrate the therapeutic effectiveness of a
recombinant human monoclonal antibody against a human self-
antigen derived from phage display libraries in an animal model. The
ef®cacy of anti-TGF-b2 IgG4 in reducing CNS ®brosis emphasizes
the value of phage display libraries for the rapid isolation of
antibodies which are fully human with the potential for a low
frequency of both immunogenicity and side effects in therapy. Our
®ndings suggest that such TGF-b antibodies could be developed as
therapeutic anti-®brotic agents, broadly applicable to a number of
human CNS diseases in which the deposition of extracellular matrix
components is excessive.
Acknowledgements
The authors are indebted to Andrew Baird who initiated these studies withA.L. Also, the TGF-b antibody engineering and preclinical development teamsat Cambridge Antibody Technology for isolation of the VH and VL variableregions of the antibody 6B1, construction of the mammalian cell lineexpressing 6B1 IgG4, and puri®cation and characterization of the antibody.We are also grateful to Mia Martins for assistance with some of the histologyand Peter Treasure for statistical analysis of the data. This work was funded bythe International Spinal Research Trust and the Wellcome Trust.
Abbreviations
CNS, central nervous system; CSF, cerebrospinal ¯uid; CSP, chondroitinsulphate proteoglycan; dpl, days post-lesion; ED1, a marker of macrophagesand microglia; GFAP, glial ®brillary acidic protein; IgG, immunoglobulin;NIP, 4-hydroxy-3-iodo-5-nitrophenylacetic acid; TGF-b, transforming growthfactor-b; VH, variable heavy; VL, variable light.
References
Adair, J.R. & Bright, S.M. (1995) Progress with humanized antibodies ± anupdate. Exp. Opin. Invest. Drugs, 4, 863±870.
Baghdassarian-Chalaye, D., Toru-Delbauffe, D., Gaveret, J.M. & Pierre, M.(1993) Effects of transforming growth factor b1 on the extracellular matrixand cytoskeleton of cultured astrocytes. Glia, 7, 193±202.
Baselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C.C., Dantis,L., Sklarin, N.T., Seidman, A.D., Hudis, C.A., Moore, J., Rosen, P.P.,Twaddell, T., Henderson, I.C. & Norton, L. (1996) Phase II study of weeklyintravenous recombinant humanized anti-p185HER2 monoclonal antibodyin patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin.Oncol., 14, 737±744.
Crowe, J.E., Murphy, B.R., Chanock, R.M., Williamson, R.A., Barbas III, C.F.& Burton, D.R. (1994) Recombinant human respiratory syncytial virus(RSV) monoclonal antibody Fab is effective therapeutically whenintroduced directly into the lungs of RSV-infected mice. Proc. Natl Acad.Sci. USA, 91, 1386±1390.
Cui, W. & Ackhurst, R.J. (1996) Transforming growth factor bs: Biochemistryand biological activities in vivo and in vitro. In LeRoith, D. & Bondy, C.(eds), Growth Factors in Health and Disease. JAI Press, Greenwich,Connecticut, pp. 319±356.
Flanders, K., Ludecke, G., Renzing, J., Hamm, C., Cissel, D. & Unsicker, K.(1993) Effects of TGFbs and bFGF on astroglial cell growth and geneexpression in vitro. Mol. Cell. Neurosci., 4, 406±417.
Gagelin, C., Pierre, M., Gaveret, J.-M. & Toru-Delbauffe, D. (1995) RapidTGFb1 effects on actin cytoskeleton of astrocytes: comparison with otherfactors and implications for cell motility. Glia, 13, 283±293.
Grif®ths, A.D., Malmqvist, M., Marks, J.D., Bye, J.M., Embleton, M.J.,McCafferty, J., Baier, M., Holliger, K.P., Gorick, B.D. & Hughes-Jones,N.C. (1993) Human anti-self antibodies with high speci®city from phagedisplay libraries. EMBO J., 12, 725±734.
Heino, J. & Massague, J. (1989) Transforming growth factor b switches thepattern of integrins expressed in MG-63 human osteosarcoma cells andcauses a selective loss of cell adhesion to laminin. J. Biol. Chem., 36,21 806±21 811.
Hurwitz, A., Lyman, W. & Berman, J. (1995) Tumour necrosis factor alphaand transforming growth factor b upregulate astrocyte expression ofmonocyte chemoattractant protein ± 1. J. Neuroimmunol., 57, 193±198.
Ignotz, R.A., Heino, J. & Massague, J. (1989) Regulation of cell adhesionreceptors by transforming growth factor b. Regulation of vitronectinreceptor and LFA-1. J. Biol. Chem., 264, 389±392.
Ignotz, R.A. & Massague, J. (1989) Transforming growth factor b stimulatesthe expression of ®bronectin and collagen and their incorporation into theextracellular matrix. J. Biol. Chem, 261, 4337±4345.
Jackson, H., Bacon, L., Pedley, B., Derbyshire, E., Field, A., Osbourn, J. &Allen, D. (1998) Antigen speci®city and tumour targeting ef®ciency of ahuman CEA speci®c scFv and af®nity matured derivatives. Brit. J. Cancer.(in press).
Kerr, L.D., Miller, D.B. & Matrisian, L.M. (1990) TGFb1 inhibition oftransin/stromelysin gene expression is mediated through a Fos bindingsequence. Cell, 61, 267±278.
Kitazawa, K. & Tada, T. (1994) Elevation of transforming growth factor-b incerebrospinal ¯uid of patients with communicating hydrocephalus after sub-arachnoid haemorrhage. Stroke, 25, 1400±1404.
Inhibition of glial scarring in the injured brain 2373
Ó 1999 European Neuroscience Association, European Journal of Neuroscience, 11, 2367±2374
Krupinski, J., Kumar, P., Kumar, S. & Kaluza, J. (1996) Increased expressionof TGF-b in brain tissue after ischemic stroke in humans. Stroke, 27, 852±857.
Labourdette, G., Thiery, J., Laeng, P., Perraud, F., Lawrence, D. & Pettman, B.(1990) Transforming growth factor b1 modulates the effects of basic®broblast growth factor on growth and phenotypic expression of ratastroblasts in vitro. J. Cell Biol., 144, 473±484.
Laiho, M., Saksela, O., Andreasen, P.A. & Keski-Oja, J. (1986) Enhancedproduction and extracellular deposition of the endothelial-type plasminogenactivator inhibitor in cultured human lung ®broblasts by transforminggrowth factor b. J. Cell Biol., 103, 2403±2410.
Logan, A. & Berry, M. (1994) Cellular response of central nervous systemtissue to invasive therapeutic measures. Meth. Neurosci., 21, 3±19.
Logan, A., Berry, M., Gonzalez, A.M., Frautschy, S.A., Sporn, M.B. & Baird,A. (1994) Effects of transforming growth factor b1 on scar production in theinjured central nervous system. Eur. J. Neurosci., 6, 355±363.
Logan, A., Frautschy, S.A., Gonzalez, A.M., Sporn, M.B. & Baird, A. (1992)Enhanced expression of transforming growth factor b1 in the rat brain aftera localised cerebral injury. Brain Res., 587, 216±225.
Lucas, C., Fendly, B.M., Mukku, V.R., Wong, W.L. & Palladino, M.A. (1991)Generation of antibodies and assays for transforming growth factor b. Meth.Enzymol., 198, 303±316.
Lund, L.R., Riccio, A., Andreasen, P.A., Nielsen, L.S., Kristensen, P., Laiho,M., Saksela, O., Blasi, F. & Dano, K. (1987) Transforming growth factor-bis a strong and fast acting positive regulator of the level of type-1plasminogen activator-inhibitor mRNA in WI-38 human lung ®broblasts.EMBO J., 6, 1281±1286.
Marks, J.D., Hoogenboom, H.R., Bonnert, T.P., McCafferty, J., Grif®ths, A.D.& Winter, G. (1991) By-passing immunization: Human antibodies from V-gene libraries displayed on phage. J. Mol. Biol., 222, 581±597.
Neri, D., Carnemolla, B., Nissim, A., Leprini, A., Querze, G., Balza, E., Pini,L., Tarli, A., Halin, C., Neri, P., Zardi, L. & Winter, G. (1997) Targeting byaf®nity-matured recombinant antibody fragments of an angiogenesisassociated ®bronectin isoform. Nature Biotech., 15, 1271±1275.
Pepper, M.S. (1997) Transforming growth factor-b: Vasculogenesis,angiogenesis and vessel wall integrity. Cytokine Growth Factor Rev., 8,21±43.
Pratt, B.M. & McPherson, J.M. (1997) TGF-bs in the central nervous system:Potential roles in ischaemic injury and neurodegenerative diseases. CytokineGrowth Factor Rev., 8, 267±292.
Randall, L.A., Wadhwa, M., Thorpe, R. & Mire-Sluis, A.R. (1993) A novel,sensitive bioassay for transforming growth factor b. J. Immunol. Meth., 164,61±67.
Roberts, A.B., Sporn, M.B., Assoian, R.K., Smith, J.M., Roche, N.S.,Wake®eld, L.M., Heine, U.I., Liotta, L.A., Falanga, V., Kehrl, J.H. &Fauci, A.S. (1986) Transforming growth factor type beta: Rapid inductionof ®brosis and angiogenesis in vivo and stimulation of collagen synthesis invitro. Proc. Natl Acad. Sci. USA, 83, 4167±4171.
Thompson, J.E., Vaughan, T.J., Williams, A.J., Wilton, J., Johnson, K.S.,Bacon, L., Green, J.A., Field, R., Ruddock, S., Martins, M., Pope, A.R.,Tempest, P.R. & Jackson, R.H. (1999) A fully human antibody neutralisingbiologically active human TGFb2 for use in therapy. J. Immunol. Meth. (inpress).
Toru-Delbauffe, D., Baghdassarian-Chalaye, D., Gaveret, J.M., Courtin, F.,Pomerance, M. & Pierre, M. (1990) Effects of transforming growth factorb1 on astroglial cells in culture. J. Neurochem., 54, 1056±1061.
Varga, J., Rosenbloom, J. & Jimenez, S.A. (1987) Transforming growth factorbeta causes a persistent increase in steady-state amounts for type I and typeIII collagen and ®bronectin mRNAs in normal dermal human ®broblasts.Biochem. J., 297, 597±604.
Vaughan, T.J., Williams, A.J., Pritchard, K., Osbourn, J.K., Pope, A.R.,Earnshaw, J.C., McCafferty, J., Hodits, R.A., Wilton, J. & Johnson, K.S.(1996) Human antibodies with sub-nanomolar af®nities isolated from alarge non-immunized phage display library. Nature Biotech., 14, 309±314.
Wahl, S.M., Hunt, D.A., Wake®eld, L.M., McCartney-Francis, N., Wahl,L.M., Roberts, A.B. & Sporn, M.B. (1987) Transforming growth factor binduces monocyte chemotaxis and growth factor production. Proc. NatlAcad. Sci. USA, 84, 5788±5792.
Wrana, J.L., Sodek, J., Ber, R.L. & Bellows, C.G. (1986) The effects ofplatelet-derived transforming growth factor-b on normal diploid gingival®broblasts. Eur. J. Biochem., 159, 69±76.
Wyss-Coray, T., Masliah, E., Mallory, M., McConlogue, L., Johnson-Wood,K., Lin, C. & Mucke, L. (1997) Amyloidogenic role of cytokine TGF-b1 intransgenic mice and in Alzheimer's disease. Nature, 389, 603±606.
2374 A. Logan et al.
Ó 1999 European Neuroscience Association, European Journal of Neuroscience, 11, 2367±2374